{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Enfortumab Vedotin Related Rash', \"In the phase 1 study [Study ASG-22CE-13-2]. rash and similar dermatologic AE's were\", 'common among patients treated with EV, and were seen more frequently at the highest dose.', 'Although the exact etiology of dermatologic toxicities associated with EV is unclear at this', 'time, due to the expression of nectin-4 in the skin, rash maybe an on target toxicity. The most', 'common type of dermatological AE reported in ASG-22CE-13-2 was maculo-papular rash,', 'rash, skin exfoliation, and skin pigmentation disorder. Most occurred early on (during', 'cycle 1), and some were associated with pruritus. Mild rash due to EV should be treated', 'using local supportive care as needed. Topical corticosteroids have been used along with', 'antihistamines for pruritus as needed. Grade 3 rash that is not limiting self-care activities of', 'daily living or associated with infection requiring systemic antibiotics does not require', 'treatment interruption, provided symptoms are not severe and can be managed with', 'supportive treatment.', 'Management of Hyperglycemia', 'Investigators should monitor blood glucose levels and are advised to perform additional', 'assessments if any symptoms of hyperglycemia are observed, including a thorough', 'evaluation for infection. In addition, if steroids are used to treat any other condition, blood', 'glucose levels may require additional monitoring. If elevated blood glucose levels are', 'observed, subjects should be treated according to local standard of care and referral to', 'endocrinology may be considered.', 'Subjects, especially those with a history of or ongoing diabetes mellitus or hyperglycemia,', 'should be advised to immediately notify their physician if their glucose level becomes', 'difficult to control or if they experience symptoms suggestive of hyperglycemia such as', 'frequent urination, increased thirst, blurred vision, fatigue, and headache.', 'Subjects who enter the study with an elevated HbA1c ( 6.5%) at baseline should be referred', 'to an appropriate provider during Cycle 1 for glucose management. Blood glucose should be', 'checked prior to each dosing and dose should be withheld for blood glucose > 250 mg/dL', \"(13.9 mmol/L) (Grade 3 or higher). Dosing may continue once the subject's blood glucose\", 'has improved to < Grade 2 and subject is clinically and metabolically stable. Blood glucose', '> 500 mg/dL (27.8 mmol/L) (Grade 4) considered related to EV requires treatment', 'discontinuation. If a subject experiences new onset diabetes mellitus, evaluate subjects with a', 'metabolic panel, urine ketones, glycosylated hemoglobin, and C-peptide to assess for new', 'onset type 1 diabetes in the setting of prior CPI.', 'Management of Enfortumab Vedotin Infusion Related Reactions (IRR)', 'An IRR may occur during the infusion of study treatment. The infusion should be', 'administered at a site properly equipped and staffed to manage anaphylaxis should it occur.', 'All supportive measures consistent with optimal patient care should be given throughout the', 'study according to institutional standards. Supportive measures may include administering', 'medications for IRRs.', '14 Sep 2020', 'Astellas', 'Page 59 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Subjects who have experienced an IRR may be premedicated for subsequent infusions.', 'Premedication may include pain medication (e.g., acetaminophen or equivalent), an', 'antihistamine (e.g., diphenhydramine hydrochloride), and a corticosteroid administered', 'approximately 30-60 minutes prior to each infusion or according to institutional standards.', 'Should a subject experience IRRs in the setting of premedication, continued treatment with', 'enformtumab vedotin must be discussed with the medical monitor prior to the next planned dose.', 'If anaphylaxis occurs, study treatment administration should be immediately and', 'permanently discontinued.', '5.1.2.2 Dose Modification for treatment with Docetaxel, Paclitaxel or Vinflunine', 'In general, treatment with the chemotherapy comparators (docetaxel, paclitaxel or vinflunine)', 'should be withheld for drug-related Grade 4 hematologic toxicities and for non-hematologic', 'toxicity > Grade 3, and subsequent doses modified as per Table 6 below. Dose modifications', 'will be applied for all subsequent doses. Specific dose modification guidance for docetaxel,', 'paclitaxel, and vinflunine is found below in [Sections 5.1.2.3', '5.1.2.4', 'and 5.1.2.5', 'Dose', 'modifications should also be considered according to local product labels or SmPC and', 'institutional guidelines. For docetaxel, paclitaxel or vinflunine associated hematologic', 'toxicities > 3, transfusions or growth factors may be used as indicated per institutional', 'guidelines.', 'Table 6', 'Dose Modification Guidelines for Drug-Related Adverse Events on the', 'Active Comparator Arm', 'Dose', 'Treatment', 'Toxicity*', 'Grade', 'Occurrence', 'Hold Treatment', 'Modification', 'Discontinuation', 'Neutropenia', 'Grade 1, 2,', 'All', 'Hold treatment', 'NA', 'NA', '3 or Grade 4', 'until neutrophils', 'lasting V 7 days', 'recover to', '> 1500 cells/mm\u00b3', 'Grade 4', '1st', 'Hold treatment', 'Restart treatment', 'Treatment', 'lasting > 7 days', 'until neutrophils', 'at:', 'Discontinuation', 'recover to', 'Paclitaxel:', 'should be', '> 1500 cells/mm\u00b3', '135 mg/m\u00b2', 'considered', 'Docetaxel:', '60 mg/m\u00b2', 'Vinflunine:', '280 mg/m\u00b2', '2nd', 'Hold treatment', 'Restart treatment', 'Treatment', 'until neutrophils', 'at:', 'Discontinuation', 'recover to', 'Paclitaxel:', 'should be', '> 1500 cells/mm\u00b3', '100 mg/m\u00b2', 'considered', 'Docetaxel:', '50 mg/m\u00b2', 'Vinflunine:', '250 mg/m\u00b2', '3rd', 'Yes', 'NA', 'Yes', 'Table continued on next page', '14 Sep 2020', 'Astellas', 'Page 60 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}